The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Abstract
A reduced-intensity preparative regimen consisting of melphalan and a purine analog was evaluated for allogeneic transplantation in 86 patients who had a variety of hematologic malignancies and were considered poor candidates for conventional myeloablative therapies because of age or comorbidity. Seventy-eight patients received fludarabine 25 mg/m2 daily for 5 days in combination with melphalan 180 mg/m2 (n = 66) or 140 mg/m2 (n = 12). Eight patients received cladribine 12 mg/m2 continuous infusion for 5 days with melphalan 180 mg/m2. The median age was 52 years (range, 22-70 years). Disease status at transplantation was either first remission or first chronic phase in 7 patients, untreated first relapse or subsequent remission in 16 patients, and refractory leukemia or transformed chronic myelogenous leukemia in 63 patients. Nonrelapse mortality rates on day 100 were 37.4% for the fludarabine/melphalan combination and 87.5% for the cladribine/melphalan combination. The median percentage of donor cells at 1 month in 75 patients was 100% (range, 0%-100%). The probability of grade 2-4 and 3-4 acute graft-versus-host disease was 0.49 (95% CI, 0.38-0.60) and 0.29 (95% CI, 0.18-0.41), respectively. Disease-free survival at 1 year was 57% for patients in first remission or chronic phase and 49% for patients with untreated first relapse or in a second or later remission. On multivariate analysis the strongest predictor for disease-free survival was a good or intermediate risk category. In summary, fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“N 86 Median age, y (range) 52 (22-70) Sex 52 M, 34 F Diagnosis and status at transplantation AML/MDS 43 CR1 1 Untreated 1st relapse 10 Remission $ CR2 5 Refractory 27 CML 27 CR1 6 Transformed 21 ALL/lymphoma 16 Remission $ CR2 1 Refractory 15 Median no.”
GLUCKSBERG, H., STORB, R., FEFER, A., BUCKNER, C. D., NEIMAN, P. E., CLIFT, R. A., LERNER, K. G., & THOMAS, E. D. (1974) · Transplantation · doi:10.1097/00007890-197410000-00001 · Cited by 3,694
Chronic graft-versus-host syndrome in man
Shulman, H. M., Sullivan, K. M., Weiden, P. L., McDonald, G. B., Striker, G. E., Sale, G. E., Hackman, R., Tsoi, M.-S., Storb, R., & Donnall Thomas, E. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90380-0 · Cited by 2,406
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) · Blood · doi:10.1182/blood.v91.3.756 · Cited by 2,071
Giralt, S., Estey, E., Albitar, M., van Besien, K., Rondón, G., Anderlini, P., O'Brien, S., Khouri, I., Gajewski, J., Mehra, R., et al. (1997) · Blood · doi:10.1182/blood.v89.12.4531 · Cited by 1,138
Self-citationRegimen-related toxicity in patients undergoing bone marrow transplantation.
Bearman, S. I., Appelbaum, F. R., Buckner, C. D., Petersen, F. B., Fisher, L. D., Clift, R. A., & Thomas, E. D. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.10.1562 · Cited by 868
Cited by
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Defining the Intensity of Conditioning Regimens: Working Definitions
Bacigalupo, A., Ballen, K., Rizzo, D., Giralt, S., Lazarus, H., Ho, V., Apperley, J., Slavin, S., Pasquini, M., Sandmaier, B. M., et al. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.07.004 · Cited by 1,816
Self-citationTomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Conditioning regimens for hematopoietic cell transplantation: one size does not fit all
Gyurkocza, B., & Sandmaier, B. M. (2014) · Blood · doi:10.1182/blood-2014-02-514778 · Cited by 614
Metadata
- Authors
- Giralt, S., Thall, P. F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Donato, M., Bruton, J., Cohen, A., Davis, M., Andersson, B. S., Anderlini, P., Gajewski, J., Kornblau, S., Andreeff, M., Przepiorka, D., Ueno, N. T., Molldrem, J., & Champlin, R.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-02-01
- Volume
- 97
- Issue
- 3
- Pages
- 631-637
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2155437870
- Cited by
- 568
- References
- 18
- FWCI
- 31.02
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. https://app.cochat.ai/papers/10.1182/blood.v97.3.631
- The paper
- Giralt, S., Thall, P. F., Khouri, I., Wang, X., Braunschweig, I., Ippolitti, C., Claxton, D., Donato, M., Bruton, J., Cohen, A., Davis, M., Andersson, B. S., Anderlini, P., Gajewski, J., Kornblau, S., Andreeff, M., Przepiorka, D., Ueno, N. T., Molldrem, J., & Champlin, R. (2001). Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. https://doi.org/10.1182/blood.v97.3.631
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.